Translation. Region: Russian Federation –
Source: Novosibirsk State University –
An important disclaimer is at the bottom of this article.
The 10th School of Synthetic Biology and Industrial Pharmacy opened at Novosibirsk State University. This year, it was organized by the NSU Advanced Engineering School (AES), Institute of Medicine and Medical Technologies (IMMT) NSU and the HealthNet NTI Infrastructure Center. Thirty-five students from 20 universities across the country—from Novosibirsk, Kazan, St. Petersburg, Tomsk, Krasnoyarsk, Moscow, Chelyabinsk, Vladivostok, and other cities—are participating in the event. Over 200 applications were received from students across more than 30 regions of the Russian Federation. The event will take place from January 26 to 30, 2026, at the new NSU campus.
Over the course of five days, school participants will gain insight into technologies for managing the properties of biological objects, bioinformatics tools, modern approaches to drug development, and current technological and regulatory trends. Leading pharmaceutical specialists, as well as experts from universities and research organizations, will deliver plenary lectures.
Irina Manuilova, Deputy Governor of the Novosibirsk Region, welcomed the school participants:
The School of Synthetic Biology and Industrial Pharmaceutics is focused on fostering strong ties between science and business, enabling unique collaboration between universities, research centers, and the real economy. This is the 10th time it has been held at NSU, and it's no coincidence.
NSU has become the center of a complex scientific and industrial ecosystem, which includes scientific centers of Akademgorodok, high-tech innovative companies of Akadempark, as well as industrial associations of our region and leading Russian corporations (Gazprom Neft, SIBUR, Pharma, Generium).
Participants will spend a week conducting research and solving practical cases—assignments from the field of biotechnology submitted by pharmaceutical companies.
An important element of the school will be its educational program: students will be introduced to the best modern practices in drug development, including the use of neural networks and molecular doping.
The students will also learn about the unique research opportunities available at the SKIF Center for Collective Use, a new mega-science facility in the science city of Koltsovo.
Holding such schools helps develop talented scientists and promotes the innovation and competitiveness of Russian companies.
School participants will solve bioinformatics problems and conduct experimental work in a molecular biology lab, including DNA extraction, bacterial cell transformation, and PCR analysis. They will also participate in practical training on the preparation of dosage forms and the quality control of medicinal raw materials. Furthermore, they will learn how molecular docking is used in pharmaceutical development.
Sergey Golovin, Director of the NSU Advanced Engineering School, discussed the master's programs offered by the NSU Advanced Engineering School and the educational model, which combines strong fundamental training with connections to the real sector and work on tasks submitted by high-tech companies and enterprises. He focused on one of the programs, "Advanced engineering solutions for biotechnology and medicine".
What's so interesting about this program is that we have a very large number of partners, representing both large and small businesses. All our students, in addition to learning many interesting things in their core educational courses, also implement their own project. Their project is a real, valuable challenge, and solving it forms the foundation of their education. There are opportunities to take practical courses both at our university and with our partners—all of this gives our students a very broad perspective, both in terms of their understanding of the tasks at hand and in terms of their future employment opportunities. I'm confident that working here for a week and interacting with our students will ultimately convince you that Novosibirsk is a wonderful place to study, network, and develop your career.
In 2025, the Institute of Medicine and Medical Technologies (IMMT) opened at NSU, launching new educational programs—Medical Cybernetics and Industrial Pharmacy. This year, construction is scheduled to be completed on two buildings on the NSU campus—the IMMT Educational and Research Center and the NSU Research Center, where biotechnology and biomedicine will be key areas of focus. Thanks to modern infrastructure, laboratories, and pilot production facilities, students will have the opportunity to practice solving problems from leading pharmaceutical companies while still studying.
"Regarding structural biology and industrial information, these are the sciences that have advanced very rapidly. And the future of medicine and biology lies precisely in learning these skills. Why? Because we're no longer just talking about a pill anyone can take that helps, but about targeted therapy. To create any drug tailored to the individual patient, a diagnostic panel is needed. I'm a practicing physician, but being involved in both clinical and scientific work gives me a great boost in my development. Therefore, it's important that, even during your studies, you can combine both science and practice and strive to implement your projects," noted Yulia Samoylova, Director of the Institute of Medical and Technical Technologies at NSU.
The 7th finals of the National Technology Olympiad's student track, "Genome Editing," are taking place alongside the School of Synthetic Biology and Industrial Pharmacy. Nine students from four leading universities across the country are participating. Over the course of three days, students will solve Olympiad problems posed by research fellows from their institutes and experts from companies in the real sector. All assignments in the finals are practical and aimed at implementing the country's scientific and technological development strategy.
The event's partners were R-Pharm, Helikon, Diaem, Khimmed, Pharma, and Vector-Best.
Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.